Optibrium Raises Equity to Drive Development of the Business
Optibrium, software developer for drug discovery, has raised investment from Kester Capital, a private equity firm, for the development of its business.
Optibrium, software developer for drug discovery, has raised investment from Kester Capital, a private equity firm, for the development of its business. The investment was announced in a Feb 10, 2021 press release.
Using the funds received from Kester Capital, Optibrium will drive commercial growth and develop new products for the improvement of speed, efficiency, and productivity of drug discovery. Lead products for Optibrium include StarDrop and Cerella. StarDrop is a suite of integrated software for small molecule design, optimization, and data analysis, and the Cerella platform delivers artificial intelligence technology that learns from complex drug discovery data to target high-potential chemical compounds.
“Optibrium is a cutting-edge software business that is driving some of the most exciting developments within computer-aided drug discovery,” said Adam Maidment, managing partner of Kester Capital, in the press release. “We had been tracking the business for some time and were really impressed by the team and the business’ achievements.”
Matt Segall, CEO of Optibrium, added in the press release, “We are delighted to have Kester Capital on board as an investment partner to continue the successful evolution of the business. Kester has extensive experience in the life sciences sector, and we are looking forward to working with them to capitalize on the substantial market opportunities.”
Source: Optibrium
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
